Anti-IL-23 therapy for the treatment of moderate-to-severe inverse psoriasis: A 52-week multicentre study.
Ceravalls J, Ruiz-Villaverde R, Armesto S, Fernández-Armenteros JM, Riera-Monroig J, Gracia-Cazaña T, Quintana-Codina M, Iglesias-Sancho M, Salleras M, Moya AI, Melgosa Ramos FJ, Ferran M.
Ceravalls J, et al. Among authors: salleras m.
J Eur Acad Dermatol Venereol. 2024 Sep 13. doi: 10.1111/jdv.20346. Online ahead of print.
J Eur Acad Dermatol Venereol. 2024.
PMID: 39269142
No abstract available.